Pigment Solution Program

PreclinicalSmall molecule

Pigment Solution Program is one of 24 small molecule programs targeting Adjuvant Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adjuvant TherapyUnknown status

Adjuvant TherapyPreclinical

Unknown status

Competition

Competitive Landscape

25 competitors in Adjuvant Therapy

#DrugCompanyPhaseTrials

Verzenio

Eli Lilly

Phase 3

1 2

Cialis

Eli Lilly

Phase 3

1 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 5

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 3

2 6

Ensacove

XXcovery Holdings, Inc.

Phase 3

1 7

Herceptin

OOrganon and Co

Phase 3

1 8

Imfinzi

AstraZeneca

Phase 2

2 9

Beyfortus

BeiGene

Phase 2

2 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adjuvant Therapy1 trial

Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma

Unknown status·DDr.dr.Irma Bernadette, SpKK (K)·N/A·NCT06174545·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pigment Solution Program. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pigment Solution Program compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pigment Solution Program. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr.dr.Irma Bernadette, SpKK (K) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDr.dr.Irma Bernadette, SpKK (K)

Pigment Solution Program

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News